EMMA News and Press, Emmaus Life Sciences Incorporation From 03/24/20

NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its inaugural event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...

TORRANCE, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease (SCD) treatment, announced today several steps it has taken in response to the Coronavirus (COVID-19) pandemic. Within the overall SCD community, Emmaus is workin...

TORRANCE, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB:EMMA), a leader in sickle cell disease treatment, today announced that Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer, and Jay Sherwood, Chief Financial Officer, will presen...

-- Company Reports Highest Gross Monthly Sales of 2019 and  Total Gross Sales of $7.8 Million in the Fourth Quarter -- TORRANCE, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease (SCD) treatment, today reported pr...

TORRANCE, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, announced today the top-line preliminary results in the first patient in the company’s Pilot/Phase 1 study in the treatment of diverticulosis. Th...

Quick Take Beam Therapeutics ( BEAM ) intends to raise $100 million from the sale of its common stock, per an amended registration statement . The company is advancing a pre-clinical set of programs for the treatment of various diseases that may possibly be treated via gene editing of a s...

TORRANCE, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, responded today to the draft evidence report by ICER dated January 23, 2020 examining the effectiveness and value of Crizanlizumab, Voxelotor, and L-glu...

TORRANCE, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, is pleased to announce a new adherence program available to sickle cell disease (SCD) patients in collaboration with US Bioservices, an AmerisourceBerge...

TORRANCE, Calif., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, today reported that it received the initial purchase order relating to taiba Healthcare’s early access program for Endari® (L-glutamine oral...

TORRANCE, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, today reported that it expects to receive shortly the initial purchase orders relating to taiba Healthcare’s early access program for Endari®...